Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pexidartinib in Tenosynovial Giant Cell Tumor
NCT04488822Phase 3Active, not recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Sep 2020
- Primary completion
- Oct 2021
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 2
01
Overview
A Phase 3 trial of pexidartinib in tenosynovial giant cell tumor (TGCT), sponsored by Daiichi Sankyo Co., Ltd.. Started Sep 2020; status: active, not recruiting.
02
Drugs
pexidartinib
03
Conditions
tenosynovial giant cell tumor (TGCT)
Beyond the preview
Go deeper on NCT04488822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04488822.